Partnerships
Partnerships
The University of Washington (UW)
The University of Washington (UW) and ContextVision have established a strategic partnership aimed at enhancing the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). This collaboration focuses on developing advanced imaging biomarkers through the integration of artificial intelligence (AI) and high-quality imaging data.
Broader Impact
This partnership represents a significant step in ContextVision’s expansion into the data quality domain, moving beyond traditional image enhancement to focus on the development of digital biomarkers. The tools and methodologies developed through this collaboration have the potential to revolutionize the early detection and monitoring of liver diseases, ultimately improving patient outcomes.
ContextVision and the University of Washington sign a partnership agreement to advance liver disease diagnosis
University of Waterloo (LITMUS)
The University of Waterloo’s Laboratory on Innovative Technology in Medical Ultrasound (LITMUS) has partnered with ContextVision to improve liver disease diagnostics using advanced ultrasound imaging and artificial intelligence (AI).
Broader Impact
This initiative is part of ContextVision’s broader strategy to engage with global ultrasound players, securing additional expertise and analytical support to drive advancements in data quality and clinical applications for ultrasound-based solutions. The collaboration aims to create a strong research ecosystem that fosters innovation in liver disease quantification and beyond.
InPhase Solutions
InPhase Solutions AS, a Norway-based expert in ultrasound technology development and consultancy, has partnered with ContextVision to advance ultrasound diagnostics for metabolic dysfunction-associated steatotic liver disease (MASLD). This collaboration aims to enhance ContextVision’s internal research and development efforts, particularly in quantitative imaging and AI-powered ultrasound technologies.
Broader Impact
This partnership is part of ContextVision’s broader strategy to engage with global ultrasound players, securing additional expertise and analytical support to drive advancements in data quality and clinical applications for ultrasound-based solutions. By building a strong research ecosystem, the collaboration aims to create the foundation for breakthrough innovations in liver disease quantification.
AMRA Medical
We have partnered up with AMRA Medical as a part of the Data Quality program initiative – setting a new standard in non-invasive MASLD detection and staging.
AMRA Medical contributes its MRI‑based body composition analysis, including measurements of liver fat (PDFF), abdominal fat volumes, and muscle mass, with the goal to enhance multimodal liver disease diagnostics, specifically targeting metabolic dysfunction‑associated steatotic liver disease (MASLD).
By integrating MRI-driven data with our ultrasound-based AI biomarkers, we want to correlate modalities and boost the accuracy and staging capabilities of non-invasive diagnostics.
Why it matters
MASLD affects approximately one in four people globally and is rapidly becoming one of the leading causes of chronic liver disease. The need for non-invasive, cost-effective diagnostic solutions is urgent – particularly as current methods often miss early stages of disease.
Beyond Imaging: The Transformation to Data Quality
Building on more than 40 years of leadership in medical image enhancement, ContextVision is advancing its legacy through the transformation to Data Quality— a focused ultrasound program that leverages AI-powered image-enhancements to enable organ and disease specific quantitative imaging solutions to point-of-care ultrasound.
The goal is to deliver a more rapid and accurate detection as well as staging of chronic conditions, such as MASLD (Metabolic dysfunction-associated steatotic liver disease). By combining organ-specific image enhancement, user-independent workflows, as well as quantitative disease-specific digital biomarkers, the platform is being built to support near-patient diagnostic solutions.
Why Data Quality matters?
Chronic diseases like MASLD affect more than 25% of the global population. Traditional patient journeys are dependent on multiple clinical specialists, diagnostic technologies, and care settings, which results in a diagnostic pathway that is costly and hard to scale. That’s why ContextVision is developing solutions designed to simplify patient journeys by facilitating a timely diagnostic and treatment decision— directly at the point of care.
Innovating for our Customers
The Data Quality Initiative builds on our proven Image Quality expertise and is being developed as a modular add-on. Its architecture is intended to let OEM partners explore organ- and disease specific feature enhancements as well as quantitative solutions for digital biomarkers in their ultrasound systems with or without workflow adjustments.
By targeting standardized outputs and user-independent interpretation, the program aims to reduce variability and support more consistent diagnostics across product lines. The goal is to give OEMs the freedom to customize now and the headroom to scale later—advantages that matter in a fast-moving near-patient imaging market.
Further reading:
Press Release – Organ-specific Data Quality launch (18 July 2024)
Press Release – UW, Waterloo & InPhase partnerships (8 April 2025)
ContextVision 1st Target is Liver Diagnostics
In late 2024, the Data Quality project reached a major milestone: a formal partnership with the University of Washington focused on developing digital biomarkers for early detection and monitoring of liver disease. To accelerate progress, ContextVision has also onboarded the University of Waterloo and InPhase Solutions AS, adding specialized ultrasound and quantitative imaging expertise to the team. And this is only the beginning – we look forward to announcing more partnerships soon.